Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator’s Choice of Chemotherapy ... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'A single-ascending and multiple-ascending dose study to evaluate the safety, tolerability, pharmaco... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembro... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Eff... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Pla... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'An Open-Label, Rollover Study for Participants with Thyroid Eye Disease Previously Enrolled in Amge... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structu... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Open-Label, Randomized, Crossover Study to Investigate the Relative Bioavailability of A... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'Solid tumor Study for Long term Treatment of Cancer Patients Who Have Participated in BMS-Parent St... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'A Global, Multicentre, Phase II Platform Study of Datopotamab Deruxtecan (Dato-DXd)-based Combinati... Read More